THE SENATE TWENTY-SEVENTH LEGISLATURE, 2014 STATE OF HAWAII

S.B. NO. 2882 S.D. 1

A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1.	Section 329-14,	Hawaii	Revised	Statutes,	is
2	amended as follo	ws:				
3	1. By amen	ding subsection	(d) to :	read:		

4 "(d) Any material, compound, mixture, or preparation that
5 contains any quantity of the following hallucinogenic
6 substances, their salts, isomers, and salts of isomers, unless
7 specifically excepted, whenever the existence of these salts,
8 isomers, and salts of isomers is possible within the specific
9 chemical designation:

10 (1) Alpha-ethyltryptamine (AET);

11 (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);

- 12 (3) 2,5-dimethoxyamphetamine (2,5-DMA);
- 13 (4) 3,4-methylenedioxy amphetamine;
- 14 (5) 3,4-methylenedioxymethamphetamine (MDMA);
- 15 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy16 MDA);
- 17 (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
- 18 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;

Page 2

1	(9)	4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
2	(10)	4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
3	(11)	3,4,5-trimethoxy amphetamine;
4	(12)	Bufotenine;
5	(13)	4-methoxyamphetamine (PMA);
6	(14)	Diethyltryptamine;
7	(15)	Dimethyltryptamine;
8	(16)	4-methyl-2,5-dimethoxy-amphetamine;
9	(17)	Gamma hydroxybutyrate (GHB) (some other names include
10		gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
11		hydroxybutanoic acid; sodium oxybate; sodium
12		oxybutyrate);
13	(18)	Ibogaine;
14	(19)	Lysergic acid diethylamide;
15	(20)	Marijuana;
16	(21)	Parahexyl;
17	(22)	Mescaline;
18	(23)	Peyote;
19	(24)	N-ethyl-3-piperidyl benzilate;
20	(25)	N-methyl-3-piperidyl benzilate;
21	(26)	Psilocybin;
22	(27)	Psilocyn;

S.B. NO. ²⁸⁸² S.D. 1

1	(28)	1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
2	(29)	Ethylamine analog of phencyclidine (PCE);
3	(30)	Pyrrolidine analog of phencyclidine (PCPy, PHP);
4	(31)	Thiophene analog of phencyclidine (TPCP; TCP);
5	(32)	Gamma-butyrolactone, including butyrolactone;
6		butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
7		dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
8		1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
9		hydroxybutyric acid lactone; 3-hydroxybutyric acid
10		lactone and 4-hydroxybutanoic acid lactone with
11		Chemical Abstract Service number 96-48-0 when any such
12		substance is intended for human ingestion;
13	(33)	1,4 butanediol, including butanediol; butane-1,4-diol;
14		1,4- butylenes glycol; butylene glycol; 1,4-
15		dihydroxybutane; 1,4- tetramethylene glycol;
16		tetramethylene glycol; tetramethylene 1,4- diol with
17		Chemical Abstract Service number 110-63-4 when any
18		such substance is intended for human ingestion;
19	(34)	2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
20		its optical isomers, salts, and salts of isomers;
21	(35)	N-benzylpiperazine (BZP; 1-benzylpiperazine) its
22		optical isomers, salts, and salts of isomers;

S.B. NO. ²⁸⁸² S.D. 1

1	(36)	1-(3-trifluoromethylphenyl)piperazine (TFMPP), its
2		optical isomers, salts, and salts of isomers;
3	(37)	Alpha-methyltryptamine (AMT), its isomers, salts, and
4		salts of isomers;
5	(38)	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its
6		isomers, salts, and salts of isomers;
7	(39)	Salvia divinorum;
8	(40)	Salvinorin A;
9	(41)	Divinorin A; [and]
10	(42)	5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some
11		trade or other names: 5-methoxy-3-[2-
12		(dimethylamino)ethyl]indole; 5-MeO-DMT)[.] <u>;</u>
13	(43)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
14	(44)	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
15	(45)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
16	(46)	2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
17	(47)	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-
18		<u>2);</u>
19	(48)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
20		<u>(2C-T-4);</u>
21	(49)	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
22	(50)	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

S.B. NO. ²⁸⁸² S.D. 1

1	(51)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
2	(52)	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
3		methoxybenzyl)ethanamine, its optical, positional, and
4		geometric isomers, salts, and salts of isomers (Other
5		<pre>names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);</pre>
6	(53)	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
7		methoxybenzyl)ethanamine, its optical, positional, and
8		geometric isomers, salts, and salts of isomers (Other
9		names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and
10	(54)	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
11		methoxybenzyl)ethanamine, its optical, positional, and
12		geometric isomers, salts, and salts of isomers (Other
13		names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)."
14	2.	By amending subsection (g) to read:
15	"(g)	Any of the following cannabinoids, their salts,
16	isomers,	and salts of isomers, unless specifically excepted,
17	whenever	the existence of these salts, isomers, and salts of
18	isomers i	s possible within the specific chemical designation:
19	(1)	Tetrahydrocannabinols; meaning tetrahydrocannabinols
20		naturally contained in a plant of the genus Cannabis
21		(cannabis plant), as well as synthetic equivalents of
22		the substances contained in the plant, or in the



S.B. NO. ²⁸⁸² S.D. 1

1		resinous extractives of Cannabis, sp. or synthetic
2		substances, derivatives, and their isomers with
3		similar chemical structure and pharmacological
4		activity to those substances contained in the plant,
5		such as the following: Delta 1 cis or trans
6		tetrahydrocannabinol, and their optical isomers; Delta
7		6 cis or trans tetrahydrocannabinol, and their optical
8		isomers; and Delta 3,4 cis or trans-
9		tetrahydrocannabinol, and its optical isomers (since
10		nomenclature of these substances is not
11		internationally standardized, compounds of these
12		structures, regardless of numerical designation of
13		atomic positions, are covered);
14	(2)	Naphthoylindoles; meaning any compound containing a 3-
15		(1-naphthoyl) indole structure with substitution at
16		the nitrogen atom of the indole ring by a alkyl,
17		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
18		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
19		ethyl group, whether or not further substituted in the
20		indole ring to any extent and whether or not
21		substituted in the naphthyl ring to any extent;

S.B. NO. ²⁸⁸² S.D. 1

1	(3)	Naphthylmethylindoles; meaning any compound containing
2		a 1H-indol-3-yl-(1-naphthyl) methane structure with
3		substitution at the nitrogen atom of the indole ring
4		by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
6		2-(4-morpholinyl) ethyl group whether or not further
7		substituted in the indole ring to any extent and
8		whether or not substituted in the naphthyl ring to any
9		extent;
10	(4)	Naphthoylpyrroles; meaning any compound containing a
11		3-(1-naphthoyl) pyrrole structure with substitution at
12		the nitrogen atom of the pyrrole ring by a alkyl,
13		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
15		ethyl group whether or not further substituted in the
16		pyrrole ring to any extent, whether or not substituted
17		in the naphthyl ring to any extent;
18	(5)	Naphthylmethylindenes; meaning any compound containing
19		a naphthylideneindene structure with substitution at
20		the 3-position of the indene ring by a alkyl,

haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)



S.B. NO. ²⁸⁸² S.D. 1

1		ethyl group whether or not further substituted in the
2		indene ring to any extent, whether or not substituted
3		in the naphthyl ring to any extent;
4	(6)	Phenylacetylindoles; meaning any compound containing a
5		3-phenylacetylindole structure with substitution at
6		the nitrogen atom of the indole ring by a alkyl,
7		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
9		ethyl group whether or not further substituted in the
10		indole ring to any extent, whether or not substituted
11		in the phenyl ring to any extent;
12	(7)	Cyclohexylphenols; meaning any compound containing a
13		2-(3-hydroxycyclohexyl) phenol structure with
14		substitution at the 5-position of the phenolic ring by
15		a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
16		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
17		2-(4-morpholinyl) ethyl group whether or not
18		substituted in the cyclohexyl ring to any extent;
19	(8)	Benzoylindoles; meaning any compound containing a 3-
20		(benzoyl) indole structure with substitution at the
21		nitrogen atom of the indole ring by a alkyl,
22		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

1		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
2		ethyl group whether or not further substituted in the
3		indole ring to any extent and whether or not
4		substituted in the phenyl ring to any extent;
5	(9)	2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
6		pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
7		napthalenylmethanone (another trade name is WIN
8		55,212-2);
9	(10)	(6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
10		methyloctan-2-yl)-6a,7,10,10a-
11		tetrahydrobenzo[c]chromen-1-ol (other trade names are:
12		HU-210 and HU-211); [and]
13	(11)	Tetramethylcyclopropanoylindoles; meaning any compound
14		containing a 3-tetramethylcyclopropanoylindole
15		structure with substitution at the nitrogen atom of
16		the indole ring by an alkyl, haloalkyl, cyanoalkyl,
17		alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
18		methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
19		1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
20		morpholinyl)methyl, or tetrahydropyranylmethyl group,
21		whether or not further substituted in the indole ring

1		to any extent and whether or not substituted in the			
2	tetramethylcyclopropyl ring to any $extent[-]$; and				
3	(12)	N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,			
4		its optical, positional, and geometric isomers, salts,			
5		and salts of isomers. (Other names: APINACA, AKB48)."			
6	SECTI	ION 2. Section 329-18, Hawaii Revised Statutes, is			
7	amended by	amending subsection (c) to read as follows:			
8	"(C)	Depressants. Unless listed in another schedule, any			
9	material,	compound, mixture, or preparation containing any			
10	quantity c	of the following substances having a depressant effect			
11	on the cer	ntral nervous system:			
12	(1)	Any compound, mixture, or preparation containing			
13		amobarbital, secobarbital, pentobarbital, or any salt			
14		thereof and one or more other active medicinal			
15		ingredients which are not listed in any schedule;			
16	(2)	Any suppository dosage form containing amobarbital,			
17		secobarbital, pentobarbital, or any salt of any of			
18		these drugs and approved by the Food and Drug			
19		Administration for marketing only as a suppository;			
20	(3)	Any substance that contains any quantity of a			
21		derivative of barbituric acid or any salt thereof,			
22		including the substance butalbital;			

S.B. NO. ²⁸⁸² S.D. 1

1	(4)	Chlorhexadol;		
2	(5)	Embutramide (Tributame);		
3	(6)	Ketamine, its salts, isomers, and salts of isomers,		
4		also known as (+ or -)-2-(2-chlorophenyl)-2-		
5		(methylamino)-cyclohexanone;		
6	(7)	Lysergic acid;		
7	(8)	Lysergic acid amide;		
8	(9)	Methyprylon;		
9	(10)	Sulfondiethylmethane;		
10	(11)	Sulfonethylmethane;		
11	(12)	Sulfonmethane;		
12	(13)	Tiletamine/Zolazepam (Telazol, 2-(ethylamino)-2-(-		
13		thienyl)-cyclohexanone, flupyrazapon) or any salts		
14		thereof; [and]		
15	(14)	Gamma hydroxybutyric acid and its salts, isomers, and		
16		salts of isomers that are contained in a drug product		
17		for which an application has been approved under		
18		section 505 of the federal Food, Drug, and Cosmetic		
19		Act[+]; and		
20	(15)	Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-y1-1,2-		
21		dihydropyridin-3-yl)benzonitrile], including its		
22		salts, isomers, and salts of isomers."		



. 1	SECTION 3. Section 329-20, Hawaii Revised Statutes, is	NON 3.	5
2	amended by amending subsection (d) to read as follows:	y amend:	
3	"(d) Stimulants. Unless listed in another schedule, any	Stimu	iny
4	material, compound, mixture, or preparation which contains any	compour	any
5	quantity of the following substances having a stimulant effect	of the :	ect
6	on the central nervous system, including its salts, isomers, and	entral no	and
7	salts of such isomers whenever the existence of such salts,	such is	
8	isomers, and salts of isomers is possible within the specific	and sal	-C
9	chemical designation:	designa	
10	<pre>(1) Cathine ((+)-norpseudoephedrine);</pre>	Cathin	
11	(2) Diethylpropion;	Diethy	
12	(3) Fencamfamin;	Fencam	
13	(4) Fenproporex;	Fenpro	
14	(5) Mazindol;	Mazindo	
15	(6) Mefenorex;	Mefeno	
16	(7) Modafinil;	Modafi	
17	(8) Phentermine;	Phente:	
18	(9) Pemoline (including organometallic complexes and	Pemoli	
19	chelates thereof);	chelate	
20	(10) Pipradrol;	Piprad	
21	(11) Sibutramine; [and]	Sibutra	

S.B. NO. ²⁸⁸² S.D. 1

1	(12) SPA (1-dimethylamino-1,2-diphenylethane,	
2	lefetamine) [-]; and	
3	(13) Lorcaserin."	
4	SECTION 4. Statutory material to be repealed is bracket	ed
5	and stricken. New statutory material is underscored.	
6	SECTION 5. This Act shall take effect upon its approval	L.

Report Title:

Uniform Controlled Substances Act; Federal Conformity

Description:

2014-1133 SB2882 SD1 SMA.doc

Updates chapter 329, Hawaii Revised Statutes (HRS), to make it consistent with amendments to federal law on controlled substances. Amends sections 329-14, 329-18, and 329-20, HRS, to add new controlled substances federally scheduled as required under section 329-11, HRS. (SD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.